Cala Health Raised $77 Million To Expand Consumer Access To Wearable Bioelectronic Treatment For Essential Tremor; May Expand Into Other Indications, Including Psychiatry

Cala Health, which provides a wearable non-invasive bioelectronic therapy for adults with essential tremor raised $77 million in a funding round. Cala Health intends to use the funds to expand consumer access to its flagship product, Cala Trio, to treat essential tremor, and accelerate innovations to explore indications beyond essential tremor, including other neurological indications like Parkinson’s disease as well as targets in psychiatry, cardiology, and autoimmune disorders. To expand consumer access to Cala Trio, Cala Health plans to accelerate its relationships with payers. It intends to continue seeking reimbursement options with Medicare, commercial payers, and with payer . . .